TIM
INKT icon

Total Investment Management’s MiNK Therapeutics INKT Stock Holding History

Total Investment Management’s Portfolio INKT Stock Details INKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-500
Closed -$3.69K – 447
2025
Q2 		$3.69K Buy
+500
New +$3.76K ﹤0.01% 473

Other funds holding INKT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LF
Longbow Finance Lutry, Switzerland $782M AUM 48.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
C
Covestor London, United Kingdom $144M AUM 37.32% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Total Investment Management's INKT Position: Q3 2025 in Review

Total Investment Management sold out of MiNK Therapeutics (INKT) in Q3 2025, closing a stake of 500 shares — an estimated $3.69K sold.

Total Investment Management first reported a position in INKT in Q2 2025 and held it in 1 quarter. The position peaked at $3.69K in Q2 2025. 18 funds tracked by Wall St. Rank hold INKT as of Q3 2025.

  • Total Investment Management reported no remaining MiNK Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Total Investment Management sold 500 MiNK Therapeutics shares in Q3 2025, an estimated $3.69K.
  • Total Investment Management first reported a position in MiNK Therapeutics in Q2 2025 and held it in 1 quarter.
  • Total Investment Management's MiNK Therapeutics position peaked at $3.69K in Q2 2025.
  • 18 funds tracked by Wall St. Rank held MiNK Therapeutics as of Q3 2025.

Based on Total Investment Management's 13F filing for Q3 2025, filed 13 Nov 2025.